Psoriasis and psoriatic arthritis;Psoriasis et arthrite psoriasique

Revue Medicale de Liege

Volumn 61, Issue 5-6, 2006, Pages 334-340

  Henno, Audrey ^a   Rausin, A ^a   Malaise, M ^a   De La Brassinne, M ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Psoriasis; Psoriatic arthritis; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALEFACEPT; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCITRIOL; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN A; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; ETRETINATE; FOLIC ACID; INFLIXIMAB; KERATOLYTIC AGENT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID DERIVATIVE; SALAZOSULFAPYRIDINE; TACALCITOL; TAZAROTENE; VITAMIN D DERIVATIVE;

ARTICLE; CHRONIC DISEASE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CREAM; DOSE RESPONSE; DRUG ABSORPTION; DRUG FORMULATION; DRUG SYNTHESIS; HISTOPATHOLOGY; HUMAN; HYPERKALEMIA; HYPERLIPIDEMIA; HYPEROSTOSIS; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; LIVER DISEASE; LOTION; NEOPLASM; NEPHROTOXICITY; PARESTHESIA; PHOTOTHERAPY; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; SKIN DISEASE; SKIN INFLAMMATION; ULTRAVIOLET B RADIATION;

ARTHRITIS, PSORIATIC; HUMANS; PSORIASIS;

EID: 33745921490     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Galadari H, Fuchs B. Lebwohl M.- Newly available treatments for psoriatic arthritis. Int J Dermatol, 2003, 53, 231-217.
2. Bardin T.- Psoriatic rheumatism. Rev Prat, 2004, 54, 60-68.
3. Gladman D, Antoni C, Mease P, et al.- Psoriatic arthritis: epidemiology, clinical features, course and outcome. Ann Rheum Dis, 2005, 64, 14-17.
4. Rahman P, Elder J.T.- Genetic epidemiology of psoriasis and psoriatic arthritis. Ann Rheum Dis, 2005, 64, 37-39.
5. Moll J.M, Wright V.- Familial occurrence of PsA. Ann Rheum Dis, 1973, 32, 181-201.
6. Rausin A, Henno A, de la Brassinne M.- Biological agents in the treatment of psoriasis. G Ital Dermatol Venereol, 2005, 140, 557-560.
7. Detmar M, Brown LF, Claffey KP, et al.- Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med, 1994, 180, 1141-1146.
8. Lebwohl M, Ting P T, Koo JY.- Psoriasis treatment: traditional therapy. Ann Rheum Dis, 2005, 64, 83-86.
9. Henno A, Hua MT, de la Brassinne M.- Le médicament du mois: Tazarotène 0.05%-0.1% (Zorac). Rev Med Liege, 2003, 58, 706-708.
10. Mendonça C O, Griffiths CEM.- Side effect of systemic treatment for psoriasis. Retinoids, 2004, 20, 98-101.
11. Dubertret L.- Psoriasis: une maladie de la qualité de vie. Rev Prat, 2004, 54, 17-68.
12. Nash P, Clegg D O.- Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis, 2005, 64, 74-77.
13. Sterry W, Barker J, Boehncke W, et al.- Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol, 2004, 151, 3-17.